Sunesis Pharmaceutic (SNSS) 0.54 $SNSS Sunesis Announces

New Post Public Reply Private Reply Replies (0) Message Board

Jun 12, 2016 at 9:20 AM

Sunesis Pharmaceutic (SNSS) 0.54 $SNSS

Sunesis Announces Study Examining the Value of Complete Remission Prior to HCT in Patients with AML Presented at 2016 ASCO Annual Meeting
GlobeNewswire - Mon Jun 06, 8:12AM CDT
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced the presentation of results from a study conducted by the Center for International Blood and Marrow Transplant Research (CIBMTR) at the Medical College of Wisconsin evaluating the value of achieving complete remission prior to allogeneic hematopoietic cell transplantation (HCT) in patients with acute myeloid leukemia (AML). The study was funded jointly by Sunesis and CIBMTR. The results are being presented today, Monday, June 6 from 8:00 a.m. to 11:30 a.m. Central Time at the Hematologic Malignancies - Leukemia, Myelodyplastic Syndromes, and Allotransplant General Poster Session of the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois.
SNSS: 0.54 (-0.01)

Sunesis Pharmaceuticals Appoints Linda Neuman, M.D., as Vice President, Clinical Development
GlobeNewswire - Wed Jun 01, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that Linda Neuman, M.D., has been appointed to the role of Vice President, Clinical Development. Dr. Neuman brings 10 years of clinical practice and 13 years of industry experience to Sunesis, most recently serving as Senior Medical Director of Oncology at Puma Biotechnology.
SNSS: 0.54 (-0.01), PBYI: 33.41 (-0.43)

Sunesis Pharmaceuticals Announces Support of First-Ever Acute Myeloid Leukemia Awareness Month in June
GlobeNewswire - Wed May 25, 8:00AM CDT
Sunesis Provides Educational Grant to Support Campaign Sponsor CancerCare
SNSS: 0.54 (-0.01)

Sunesis Pharmaceuticals Announces Oral Presentation on Vosaroxin at the 21st Congress of the European Hematology Association
GlobeNewswire - Thu May 19, 6:28AM CDT
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced an oral presentation on vosaroxin at the 21 Congress of the European Hematology Association (EHA) to be held June 9-12, 2016 at the Bella Center in Copenhagen, Denmark.
SNSS: 0.54 (-0.01)

Sunesis to Present at the 2016 UBS Global Healthcare Conference
GlobeNewswire - Wed May 18, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will present at the 2016 UBS Global Healthcare Conference on Wednesday, May 25 at 11:00 AM Eastern Time at The Grand Hyatt in New York City.
SNSS: 0.54 (-0.01)

Sunesis reports 1Q loss
Automated Insights - Thu May 05, 8:40AM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Sunesis Pharmaceuticals Inc. (SNSS) on Thursday reported a loss of $10.1 million in its first quarter.
SNSS: 0.54 (-0.01)

Sunesis Pharmaceuticals Reports First Quarter 2016 Financial Results and Recent Highlights
GlobeNewswire - Thu May 05, 6:01AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the first quarter ended March 31, 2016. Loss from operations for the three months ended March 31, 2016 was $10.1 million. As of March 31, 2016, cash, cash equivalents and marketable securities totaled $40.0 million.
SNSS: 0.54 (-0.01)

Sunesis to Host Conference Call on May 5th to Discuss First Quarter 2016 Financial Results and Recent Highlights
GlobeNewswire - Thu Apr 28, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that it will host a conference call on Thursday, May 5, 2016 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the first quarter ended March 31, 2016.
SNSS: 0.54 (-0.01)

Sunesis Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference
GlobeNewswire - Tue Apr 05, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will present at the 15th Annual Needham Healthcare Conference on Tuesday, April 12 at 1:40 PM Eastern Time at The Westin Grand Central in New York City.
SNSS: 0.54 (-0.01)

Sunesis Pharmaceuticals Announces Closing of $15 Million Venture Loan
GlobeNewswire - Fri Apr 01, 7:17AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it has entered into a $15 million loan agreement ("the agreement"

with Bridge Bank, a division of Western Alliance Bank and Solar Capital Ltd. (collectively, "the lenders"

.
SLRC: 18.78 (-0.07), WAL: 36.21 (-0.58), SNSS: 0.54 (-0.01)

Sunesis Pharmaceuticals Appoints Geoffrey Parker to the Board of Directors
GlobeNewswire - Mon Mar 28, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Geoffrey Parker has been appointed to the Sunesis Board of Directors. Mr. Parker brings over 30 years of finance and executive leadership experience to the Board including, most recently, serving as Executive Vice President and Chief Financial Officer of Anacor Pharmaceuticals, Inc., which he joined in 2010 at the time of its initial public offering. Sunesis also announced that Helen Kim stepped down from her position as a Director.
SNSS: 0.54 (-0.01), ANAC: 99.17 (+0.09)

Sunesis Pharmaceuticals Announces First Patient Treated in Vanderbilt University-Sponsored Phase 2 VITAL Study of Vosaroxin in Combination with Infusional Cytarabine in Patients with Previously Untreated AML
GlobeNewswire - Thu Mar 24, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the first patients have been treated in the investigator-sponsored VITAL (Vosaroxin and Infusional Cytarabine for Frontline Treatment of Acute Myeloid Leukemia) Phase 2 study of vosaroxin in combination with cytarabine in patients with previously untreated acute myeloid leukemia (AML). The trial is being conducted at the Vanderbilt-Ingram Cancer Center at Vanderbilt University under the direction of Michael R. Savona, M.D., FACP, Associate Professor of Medicine and Director of Hematology Early Therapeutics Program, and Stephen A. Strickland, M.D., MSCI, Assistant Professor of Medicine.
SNSS: 0.54 (-0.01)

Sunesis Pharmaceuticals Announces First Subject Dosed in Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062
GlobeNewswire - Wed Mar 23, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the first subject has been dosed in a Phase 1A, randomized, double-blind, placebo-controlled dose-ranging study to investigate the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of its oral, next-generation, non-covalently binding BTK-inhibitor, SNS-062, in healthy subjects. The Phase 1A study is being conducted in Belgium, pursuant to a Clinical Trial Application (CTA). With a successful study outcome, SNS-062 is expected to proceed to a Phase 1B/2 study in patients with B-cell malignancies later this year.
SNSS: 0.54 (-0.01)

Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2015 Financial Results and Recent Highlights
GlobeNewswire - Thu Mar 10, 6:00AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the fourth quarter and year ended December 31, 2015. Loss from operations for the three months and year ended December 31, 2015 was $11.3 million and $39.3 million, respectively. As of December 31, 2015, cash, cash equivalents and marketable securities totaled $46.4 million.
SNSS: 0.54 (-0.01)

Sunesis to Host Conference Call on March 10th to Discuss Fourth Quarter and Full-Year 2015 Financial Results and Recent Highlights
GlobeNewswire - Thu Mar 03, 6:00AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Thursday, March 10, 2016 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the fourth quarter and year ended December 31, 2015.
SNSS: 0.54 (-0.01)

Sunesis Pharmaceuticals Announces Promotion of Deborah A. Thomas, Ph.D., to Senior Vice President, Regulatory Affairs, Quality Assurance, and Non-Clinical Development
GlobeNewswire - Fri Feb 19, 6:00AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the promotion of Deborah A. Thomas, Ph.D., to the role of Senior Vice President, Regulatory Affairs, Quality Assurance, and Non-Clinical Development.
SNSS: 0.54 (-0.01)

Sunesis Pharmaceuticals' marketing authorisation application for Vosaroxin for AML validated by EMA
M2 - Tue Jan 05, 6:03AM CST
Biopharmaceutical company Sunesis Pharmaceuticals (NasdaqCM:SNSS) said on Monday that the European Medicines Agency (EMA) has validated the Marketing Authorisation Application (MAA) for vosaroxin for relapsed refractory acute myeloid leukemia (AML), a rapidly progressing cancer of the blood, in patients aged 60 years and older.
SNSS: 0.54 (-0.01)

Sunesis Pharmaceuticals Announces European Medicines Agency Validates Marketing Authorization Application for Vosaroxin in AML
GlobeNewswire - Mon Jan 04, 6:00AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for vosaroxin as a treatment for relapsed refractory acute myeloid leukemia (AML) in patients aged 60 years and older. Validation confirms that the submission is complete and initiates the Centralized Review process by the EMA's Committee for Medicinal Products for Human Use (CHMP). Under Centralized Review, the CHMP review period is 210 days, excluding question or opinion response periods, after which the CHMP opinion is reviewed by the European Commission, which usually issues a final decision on EU approval within three months. The MAA submission will be reviewed in the Centralized Procedure, which if authorized, provides a marketing license valid in all 28 EU member states.
SNSS: 0.54 (-0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ortho Molecular and HANS: Streamlining Functional Medicine

Functional Medicine Gets a Tech Boost The world of functional medicine just got a major shot in the arm, courtesy of an intriguing alliance between Ortho Molecular Products and HANS.FM. First of all, let's address the elephant in the room: clinicians in this field aren't exactly on a coffee break. They’re buried under mountains of paperwork, often spending hours just...

CURE Intl and Thoughtworks Step Into Digital Era

Pushing Paper Out, Digitizing In In a world where tech is king, why were hospitals—crucial, life-saving institutions—still bogged down by dusty folders and ink smudges? Well, not anymore for CURE International, not with Thoughtworks stepping up to the plate. This ain't just swapping paper for pixels; it's a lifeline for kids getting world-class surgical care without...

Jinko Solar Joins B20 Summit: Energy Forefront Focus

Jinko Solar's Invitation to the B20 Summit Never a dull moment in the solar space, especially when Jinko Solar, a big shot in clean energy, jumps into the spotlight at the B20 Summit in the U.S. Awash with high-profile discussions, Jinko's not just chatting—it's the only photovoltaic firm strutting its stuff in D.C. with gutsy calls for energy reform. Key Takeaways from...

Jubilant Eyes MPN Breakthrough with JBI-802 Data at ASH

Presenting the Case for JBI-802 From the bustling circus of drug development, here comes Jubilant Therapeutics, strutting their stuff with JBI-802, a dual inhibitor designed to tackle myeloproliferative neoplasms (MPNs) with a one-two punch. Now, they're set to drop some spicy deets at the 68th ASH Annual Meeting in New Orleans this December. So what's the fuss about?...

Agilyx's Q3 Update: GreenDot Shines Amid Mixed Results

Peeking into Agilyx's Financial Odyssey Just as I sip my morning coffee pondering the highs and lows of the market, here comes Agilyx ASA splashing some liquidity on the scene. The Q3 report paints the company in various shades—from solid greens to hesitant reds. Nothing like the thrill of untangling mixed results over a quiet day, huh? GreenDot's Climb to Profitability...

Inflatable Wonders Turn Christmas into a Hoot at Lowe's

Inflatables Bringing the Cheer (and Laughs) Well, it's that season again—where decorations either have us grumbling at the electric bill or chuckling at the lawn art. Lowe's has teamed up with Gemmy to serve a heaping platter of holiday giggles this year. They've rolled out a quirky lineup of inflatables that go from shivering Highland cows to dinosaurs and elves....

LG Innotek Scores Hat Trick with CES Innovation Wins

LG Innotek's Lighting Triumph Here we go again, LG Innotek just snagged their third CES Innovation Award in a row, this time for their cutting-edge vehicle lighting module, Nexlide C+. It's one for the books—breaking into the 2027 CES spotlight with innovative tech that not only grabs the eyes but could also steal the hearts of investors willing to bet on the future of...

RF MEDICAL Expands into Europe with New CE Certification

RF MEDICAL Secures CE Marking for Mi-BLATOR™ Just when you think the European medical device market's hit its saturation point, RF MEDICAL decides to kick the door open with their Mi-BLATOR™ microwave ablation system. This ain't just another plastic gadget, folks; it's got that shiny new CE marking under the European Union's Medical Device Regulation (MDR). Now, what...

BD Sets Stage for Investor Day in December 2026

BD's Investor Day: A Peek into the Future Say what you will about investor meets, but BD (Becton, Dickinson and Company) throwing its shindig on December 10, 2026, could be a highlight on the calendar if you're eyeing the medical technology sector. Scheduled in New York, this event is gearing up to be a canvas for BD's higher-ups to sketch out their roadmap. If you’re...

Centrus Energy Welcomes Nuclear Veteran to Leadership

Navigating a New Era at Centrus When you hear about seasoned veterans stepping up to the plate in the energy sector, it's time to perk up your ears. Centrus Energy (NYSE:LEU), a big player in nuclear fuel, just added Kevin Graney to their Board of Directors. This isn't your run-of-the-mill appointment; it packs nearly three decades of nuclear tech and national security...